<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413426</url>
  </required_header>
  <id_info>
    <org_study_id>CDAR328B2101</org_study_id>
    <nct_id>NCT00413426</nct_id>
  </id_info>
  <brief_title>Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects</brief_title>
  <official_title>An Open-labeled, Randomized, Single Dose, Three Period, 2-sequence Crossover Study to Investigate the Pharmacokinetics of Darifenacin When Given as 7.5 mg Oral Doses of a Modified Release Suspension, as Compared to the Commercial Modified Release Tablet in Healthy Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This purpose of this study is to compare the how the body changes the blood level of a single
      dose of darifenacin when given as 7.5 mg modified release tablet and the modified release
      liquid suspension (1.5 mg/ml) under fasted and fed conditions in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the PK of a single dose of 7.5 reference modified release tablet of darifenacin and the tested modified release liquid suspension (1.5 mg/ml) of darifenacin under fasted conditions in healthy subjects</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the PK of a single dose of darifenacin when given as an oral dose of a 7.5 mg modified release liquid suspension in the fed and fasted states</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <enrollment>28</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin (DAR328)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female subjects age 18 to 50 years of age (inclusive)

          -  In good health

          -  Female subjects either surgically sterilized at least 6 months prior to study
             participation or post-menopausal (no regular menstrual bleeding for at least 2 years)

          -  Body mass index within the range of 18.5 to 29.9 kg/m2 and weigh at least 45 kg

        Exclusion Criteria:

          -  Smokers

          -  History of

          -  Urinary retention, narrow-angle glaucoma, myasthenia gravis, severe hepatic
             impairment, severe ulcerative colitis, toxic megacolon

          -  Symptomatic hiatus hernia, erosive or symptomatic gastroesophageal reflux
             disease/heartburn (&gt;2 days in a week), severe constipation, gastrointestinal
             obstructive disorders, and gastric retention.

          -  Clinically significant cardiac abnormalities, fainting, low blood pressure upon
             standing, irregular heartbeats

          -  Acute or chronic bronchospastic disease (including asthma and chronic obstructive
             pulmonary disease)

          -  Clinically significant drug allergy or history of atopic allergy (asthma, urticaria,
             eczematous dermatitis)

          -  Known hypersensitivity or severe adverse event to darifenacin or similar drugs

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs or which may jeopardize participation
             in the study

          -  Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test
             result

          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  Drug or alcohol abuse within the 6 months prior to dosing

          -  Use of prescription drugs within 4 weeks prior dosing, or over-the-counter medication
             (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing.
             Paracetamol is acceptable.

          -  Participation in any clinical investigation within 4 weeks prior to dosing

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.

          -  Significant illness within 2 weeks prior to dosing.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <keyword>Pharmacokinetics</keyword>
  <keyword>oral</keyword>
  <keyword>single dose</keyword>
  <keyword>table</keyword>
  <keyword>suspension</keyword>
  <keyword>release</keyword>
  <keyword>darifenacin</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>Healthy volunteers study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

